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Abstract 
 
Background: Home-based HIV counselling and testing (HBHCT) has the potential to 
increase HIV testing uptake in sub-Saharan Africa (SSA) but data on linkage to HIV care 
after HBHCT are limited. We conducted a systematic review of linkage to care after HBHCT 
in SSA. 
 
Methods: Five databases were searched for studies published between 1st January 2000 and 
19th August 2016 that reported on linkage to care among adults newly identified with HIV 
infection through HBHCT. Eligible studies were reviewed, assessed for risk of bias and 
findings summarised using the PRISMA guidelines.  
 
Results: Fourteen studies from six countries met the eligibility criteria; nine used specific 
strategies (point-of-care CD4 count testing, follow-up counselling, provision of transport 
funds to clinic, and counsellor facilitation of HIV clinic visit) in addition to routine referral to 
facilitate linkage to care. Time intervals for ascertaining linkage ranged from one week to 
twelve months post-HBHCT. Linkage ranged from 8.2% [95% confidence interval (CI), 
6.8%-9.8%] to 99.1% (95% CI, 96.9%-99.9%). Linkage was generally lower (<33%) if 
HBHCT was followed by referral only, and higher (>80%) if additional strategies were used. 
Only one study assessed linkage by means of a randomised trial. Five studies had data on 
cotrimoxazole (CTX) prophylaxis and twelve on ART eligibility and initiation. CTX uptake 
among those eligible ranged from 0% to 100%. The proportion of persons eligible for ART 
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ranged from 16.5% (95% CI, 12.1-21.8) to 77.8% (95% CI, 40.0-97.2). ART initiation among 
those eligible ranged from 14.3% (95% CI, 0.36%-57.9%) to 94.9% (95% CI, 91.3%-97.4%). 
Additional linkage strategies, whilst seeming to increase linkage, were not associated with 
higher uptake of CTX and/or ART. Most of the studies were susceptible to risk of outcome 
ascertainment bias. A pooled analysis was not performed because of heterogeneity across 
studies with regard to design, setting, and the key variable definitions.  
 
Conclusion: Only few studies from SSA investigated linkage to care among adults newly 
diagnosed with HIV through HBHCT. Linkage was often low after routine referral but higher 
if additional interventions were used to facilitate it. The effectiveness of linkage strategies 
should be confirmed through randomised controlled trials.  
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Introduction 
Access to antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has expanded 
considerably but AIDS-related mortality remains high [1]. A major cause of this mortality is 
the late presentation of patients for treatment [2]. Early ART initiation is dependent on early 
HIV diagnosis, and prompt linkage to and retention in care [3]. HIV counselling and testing 
(HCT) is essential in expanding HIV prevention and treatment services [4]. However, HCT 
uptake in SSA remains low [5]. For instance, the proportion of HIV-positive adults in SSA 
who are aware of their HIV status has been estimated to be only 60% [6]. In order to expand 
access to HIV testing in settings with generalised HIV epidemics, the World Health 
Organisation (WHO) recommends community-based HCT with linkage to prevention, care 
and treatment services, in addition to facility-based HCT [7]. 
 
In the community-based HCT model, services are delivered through mobile, workplace-, 
school-, and home-based approaches thus removing structural, logistical, and social barriers 
to HCT [8]. Community-based HCT may also be delivered as part of multi-disease 
campaigns that involve intensive community mobilization lasting 1-2 weeks followed by 
mobile HIV testing, often coupled with other preventive medical services (campaign HCT) 
[9].  
 
Under the home-based HIV counselling and testing (HBHCT) approach, HCT services are 
conducted by trained HCT service providers in the client’s home [10]. HBHCT may be 
provided to everyone in a community through a door-to-door approach or to household 
members of known tuberculosis (TB) or HIV-positive patients [4, 10]. According to WHO, 
there were at least 39 HBHCT programmes in 10 SSA countries by early 2011 [10]. A 
systematic review published the following year found 21 studies that had reported on the 
uptake of HBHCT in SSA [11]. Since then, several studies have reported successful 
implementation of HBHCT in rural [12-24] and urban [19, 23] populations in SSA. HBHCT 
is highly acceptable and has the potential to substantially increase HIV testing uptake in SSA 
[11]. It is cost-effective at reaching previously untested persons compared with other HCT 
models in settings with high HIV prevalence [25, 26], promotes equitable access of services 
[27] and may help to promote HCT among couples [28] and prevention of mother-to-child 
HIV transmission [29]. Importantly, HBHCT facilitates early HIV diagnosis and therefore 
provides an opportunity for early linkage to care [29]. These attributes highlight the potential 
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of HBHCT as an effective platform for HIV prevention and population-based test-and-treat 
strategies.  
 
Despite these advantages, few data are available on linkage to care after HBHCT particularly 
among newly identified HIV-positive persons or on the effectiveness of strategies to increase 
linkage after HCT [30]. In the absence of interventions to facilitate linkage to care, 
individuals that test HIV positive through HBHCT may find it more challenging to enter care 
compared to those identified in facility-based HCT [31]. This is because HBHCT is more 
likely to reach socio-economically disadvantaged populations that have difficulty accessing 
healthcare services compared to facility-based HCT [32]. In order to identify effective 
linkage strategies, data are specifically required on linkage to care soon after HBHCT. The 
reasons for this include the current WHO recommendation to initiate ART among all HIV-
positive adults regardless of WHO clinical stage and at any CD4 count [33]; increasing use of 
HBHCT in Africa; and growing importance of early treatment for improved clinical 
outcomes [34-36] and HIV prevention [37]. A recent systematic review on linkage to care 
following community- and facility-based HCT [9] included 10 HBHCT studies, but did not 
distinguish linkage outcomes between HBHCT and campaign HCT, between newly and 
previously diagnosed HIV-positive individuals, or between children/adolescents and adults. 
Individuals who previously tested HIV-positive and have not yet linked to care are likely to 
differ from newly identified patients with regard to barriers that may prevent service uptake 
[12]. Similarly linkage to care among children/adolescents may be influenced by factors that 
are unique to this population [38, 39].  
 
The specific objectives of our review were to: estimate the proportion of individuals in SSA 
linking to care within 12 months among those who were newly diagnosed with HIV; the 
proportion initiating daily cotrimoxazole (CTX) prophylaxis (i.e. the people who initiated 
daily CTX prophylaxis among those who linked to care and were eligible for CTX); and the 
proportion initiating ART (i.e. the people who initiated ART among those who linked to care 
and were eligible for ART); and to summarise data on the strategies that have been used to 
increase linkage to care after HBHCT.  
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Methods 
Search strategy 
We searched five databases (Medline, Embase, Global Health, Web of Science, and Africa-
Wide information) for studies published between 1st January 2000 (time at which roll-out of 
ART programmes began in SSA [11]) and 19th August 2016. The following key terms were 
used: (HIV diagnosis OR HIV voluntary counselling and testing OR HIV testing and 
counselling OR HIV counselling and testing) AND (home based OR mobile OR community 
OR household OR door-to-door OR survey) AND (linkage OR access OR uptake OR 
enrolment OR non-enrolment OR retention OR loss to follow-up OR loss to care OR care OR 
treatment OR pre- antiretroviral therapy) AND (Africa OR individual names of countries in 
SSA). No language restriction was applied to the literature search. Identified articles were 
exported using Endnote reference management software and duplicate articles removed. Two 
authors (ER and SB) independently screened titles and abstracts of articles to identify eligible 
publications, discussed inconsistencies, and reached a consensus on their eligibility. Studies 
were eligible if they were conducted in SSA, and had original data on linkage to care among 
adults (≥18 years) newly identified with HIV infection through HBHCT, defined as HCT 
services offered in an individual’s home. Studies whose study populations included persons 
<18 years were eligible but only data for participants aged ≥18 years were utilised to estimate 
linkage and other outcomes. Studies for which the required information was not published but 
might have been collected were identified and the corresponding authors approached with 
requests for additional data. Where two or more eligible articles reported on similar or 
overlapping populations, the article with the most complete data was included. Review 
articles were excluded but their bibliographies as well as those of the identified articles were 
manually checked to identify any additional studies. Conference abstracts were excluded. All 
potentially eligible papers were then subjected to full text screening.  
 
Data extraction and synthesis 
A data extraction form was used to collect the following information from each eligible 
article: first author’s name, publication year, country and setting where study was conducted, 
study population, sample size, study design, definition of linkage to care, strategies used to 
promote and time for evaluation of linkage to care. We also obtained the number of HIV-
positive adults who were newly diagnosed, and, among those, the numbers who linked to care 
(as defined in the respective studies), and were eligible for, and initiated, CTX prophylaxis 
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and ART (based on national guidelines that were in use at the time of the respective studies). 
Risk of bias in the included studies was assessed using a component approach, similar to the 
Cochrane Collaboration’s [40], and based on three items: selection bias, outcome 
ascertainment, and attrition. The results were summarised using the PRISMA guidelines [41]. 
 
We used the reported data to calculate the proportions [and their 95% confidence intervals 
(CI), using the Clopper–Pearson method] who linked to care, initiated CTX prophylaxis, 
were eligible for and initiated ART. The denominator for linkage was all newly diagnosed 
HIV-positive adults (≥18 years) who had a potential minimum follow-up period 
corresponding to the time point when linkage was assessed (i.e. including those who out-
migrated, died, or were lost to follow-up, but excluding those who entered the study at a later 
date so had a shorter potential follow-up period). We did not stratify our linkage estimates by 
individual-level factors that may potentially influence referral uptake, such as HIV disease 
stage or CD4 count at the time of HIV diagnosis, as these data were not available for most of 
the studies. However, we compared linkage estimates between studies conducted under 
different CD4 ART eligibility thresholds i.e. ≤250 cells/μL versus ≤350 cells/μL. The 
denominator for ART eligibility was all individuals who linked within the specified time 
period, and those for initiation of CTX prophylaxis and ART were all individuals who linked 
and were eligible for CTX and ART respectively. We did not perform a meta-analysis 
because the identified studies varied widely with regard to design, setting, definition of 
linkage to care, the time points of and method for ascertaining linkage, and with regard to the 
strategies used to facilitate linkage.  
 
Results 
 
Summary of search results 
The search identified 5,905 articles of which 61 were subjected to full text screening (Figure 
1). Of those screened, 21 were eligible for detailed review; two were excluded on the basis of 
reporting on overlapping study populations [20, 42]. Of the remaining 19 articles, one [19] 
had all the required data. Additional data were obtained for 13 [12-14, 18, 21-24, 43-47] of 
the remaining 18 articles after contacting the respective corresponding authors. Thus, 14 
studies were included in the review. A summary description of the included studies is 
presented in Table 1. The studies were conducted in six countries i.e. Uganda [13, 14, 43, 
7 
 
44], South Africa [13, 14, 18, 23, 24, 45], Kenya [12, 19], Malawi [46, 47], Lesotho [22], and 
Swaziland [21] between 2005 and 2015. Most (92%) studies were based in rural [12-14, 18, 
21, 22, 24, 43, 45, 47] or semirural settings [44, 46] settings; two were conducted in both 
rural and urban [19, 23] populations. The number of newly identified HIV-positive adults 
varied widely across studies (range: 15–1637). 
 
Summary of study objectives and populations 
The included studies aimed to assess acceptability of HBHCT [18, 19, 21-24, 46, 47], and 
HIV prevalence [19], linkage to care [12-14, 18, 19, 21-24, 43-45], uptake of ART [13, 14, 
18, 24, 44, 47], and viral suppression [13, 14, 18], in the context of HBHCT. Two studies 
compared HBHCT and mobile HCT with regard to uptake and cost of HCT, HIV positivity 
rates and linkage to care [21, 22]. Three observational studies [13, 18, 44] and one 
randomised trial [14] were designed to evaluate the effect of specific interventions on linkage 
to HIV care, uptake of ART, and other outcomes. Except for one study in which HBHCT was 
provided to household contacts of TB index patients [23], all the other studies used the door-
to-door HBHCT approach. Study participants mostly comprised individuals aged ≥13 years. 
However, two studies also recruited children (<13 years) [19, 21]. With the exception of two 
studies that recruited newly identified HIV-positive individuals [22, 23], participants in other 
studies were a mixture of previously and newly identified HIV-positive patients. 
 
Risk of bias 
Only two [13, 18] studies had a low risk of bias for all assessed items (Table 2). Risk of 
selection bias was low (≥80% HBHCT coverage) in four studies [13, 18, 19, 44]. Risk of 
attrition bias was low (≥80% participant retention) in eight [13, 14, 18, 23, 24, 44-46] of ten 
studies in which participants were followed. Self-reported linkage to care was confirmed by 
tracking referrals and review of records at the referral clinic in only two studies [43, 45]. In 
the first study [43], no information was reported on the proportion of participants for whom 
clinic records were not found. In the second study [45], clinic records were found for only 
71% of the tracked referrals and self-reported data was used to ascertain linkage for the rest 
of the participants. Self-reported linkage to care was confirmed by review of documentation 
issued to patients by HIV clinics (e.g. clinic cards) in three studies [13, 14, 18]; linkage was 
not verified with the HIV clinics. In five studies [12, 21, 22, 24, 47], ascertainment of linkage 
to care was based on data from HIV clinics in the areas where the studies were conducted; 
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participants who may have linked to HIV clinics outside of the study areas were not tracked. 
Only self-reported data was used in the rest of the studies [19, 23, 44, 46].  
 
Linkage to HIV care 
In all studies, persons who tested HIV positive were referred for care. Additional strategies to 
facilitate linkage to care were used in nine (64%) [13, 14, 18, 22, 24, 43-46] of the studies 
(Table 1). These strategies included: provision of funds for transport to the HIV clinic [46]; 
follow-up counselling [13, 14, 18, 24, 43-45]; lay counsellor facilitation of the initial HIV 
clinic visits (the counsellor met the HIV-positive participant at the clinic and explained the 
clinic processes and the benefits of ART) [14]; point-of-care (POC) CD4 count [13, 14, 18, 
22] and home-based collection of samples for viral load [13] testing and provision of results. 
Linkage to care was ascertained within 3 months of HBHCT in 50% of studies [12, 19, 22, 
23, 44-46]. Ascertainment of linkage in the remaining studies was done >3 to 6 [18, 21, 43] 
and >6 to 12 [13, 14, 24, 47] months after HBHCT.  
 
Linkage to care ranged from 8.2% (95% CI, 6.8%-9.8%) [12] to 85.4% (95% CI, 75.8%-
92.2%) [14] when only referral was offered, and 24.3% (95% CI, 11.8%-41.2%) [22] to 
99.1% (95% CI, 96.9%-99.9%) [13] when referral plus additional interventions to facilitate 
linkage were offered (Table 1). In general, linkage to care was lower (<33%) in the studies 
that offered referral only [12, 19, 21, 23, 47] and higher (>80%) in those that used a 
combination of additional linkage strategies [13, 14, 18, 44].  
 
Among seven studies that were conducted in the context of a CD4 ART eligibility threshold 
of ≤250 cells/μL [12, 19, 43-47], linkage to care ranged from 8.2% (95% CI, 6.8%-9.8%) 
[12] to 81.8% (95% CI, 71.4-89.7) [44]. Linkage was lower (<30.0%) in the studies that 
offered referral only [12, 19, 47] and higher (>50%) in those that used at least one additional 
linkage strategy [43-46].  
 
Among four studies conducted in the context of a CD4 ART eligibility threshold of ≤350 
cells/μL [13, 21-23], linkage to care ranged from 24.3% (95% CI, 11.8-41.2) [22] to 99.1% 
(95% CI 96.9-99.9) [13]. Linkage was <33% in the two studies that offered referral only [21, 
23]. Linkage was also low (24.3%) in one study that used referral and POC CD4 count testing 
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[22], but very high (99.1%) in a study that offered referral, POC CD4 testing and additional 
linkage strategies [13].  
 
Uptake of CTX prophylaxis and ART 
Five studies conducted in Kenya [19], Uganda [43, 44], and Uganda and South Africa [13, 
14] had data on initiation of CTX prophylaxis among eligible individuals who linked to care. 
CTX prophylaxis is only recommended for patients with CD4 count ≤200 cells/μL, WHO 
stage 3 or 4 or HIV/TB co-infection in South Africa [48] but is routinely provided to all HIV-
positive persons irrespective of CD4 count or WHO disease stage in Uganda [49] and Kenya 
[50]. Of the studies conducted in Uganda and Kenya, additional interventions to facilitate 
referral uptake were offered in all except one. CTX uptake in these studies ranged from 
78.2% (95% CI, 69.3-85.5%) [13] to 100% [14, 43, 44] (Table 1). CTX uptake was also high 
[90.6% (95% CI, 87.3%-93.2%)] in the study that offered referral only [19]. Interventions to 
facilitate linkage were offered in the two studies that were conducted in South Africa. Uptake 
of CTX among patients with CD4 count ≤200 cells/μL in these studies ranged from 0% [14] 
to 33.3% (95% CI, 4.3-77.7) [14].  
 
Twelve studies [12-14, 18, 19, 21, 22, 24, 43-45, 47] had data on ART eligibility and ART 
initiation among patients who linked to care. The proportion of individuals eligible for ART 
initiation ranged from 16.5% (95% CI, 12.1-21.8) [45] to 77.8% (95% CI, 40.0-97.2) [22] 
(Table 1). ART uptake among those who linked to care ranged from 33.0% (95% CI, 24.2%-
41.7%) [19] to 94.0% (95% CI, 85.4%-98.3%) [47] in the studies that provided referral only. 
A similar range i.e. 14.3% (95% CI, 0.36%-57.9%) [22] to 94.9% (95% CI, 91.3%-97.4%) 
[43] was observed in the studies that provided referral plus additional linkage interventions. 
ART initiation rates were highest (≥90%) in the two studies in which HIV care services were 
provided through community-based research clinics [43, 47].  
 
Discussion 
HBHCT is increasingly being used in SSA, and an effectively conducted HBHCT strategy 
would be a key precondition for HIV control programmes that propagate a test-and-treat 
approach for HIV prevention [45]. The success of such programmes will partly depend on 
their capacity to achieve high levels of linkage to care following HIV diagnosis [16]. Hence, 
it is necessary to identify and set up strategies that will effectively link persons identified 
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with HIV through HBHCT to care and treatment. As observed in this review however, only a 
few studies have investigated linkage to care among adults newly identified with HIV 
through HBHCT in SSA. Linkage to care was below 33% in five of six studies where 
participants were only referred for care with no further interventions to facilitate referral [12, 
19, 21, 23, 47], a figure that is lower than those for client-initiated facility-based HCT (61%) 
and provider-initiated facility-based HCT (55%) [9]. With the exception of two studies [22, 
24], studies that used additional linkage strategies recorded moderate (>50% to <80%) [43, 
45, 46] to high (≥80%) [13, 14, 18, 44] levels of linkage. These trends remained irrespective 
of the CD4 ART eligibility threshold at the time of the studies. In general, linkage to care was 
highest when participants were offered POC CD4 count testing and follow-up counselling 
[13, 14, 18]. These findings suggest that HBHCT coupled with interventions to facilitate 
referral uptake may achieve similar or even higher linkage compared to facility-based HCT.  
 
WHO recommends CTX prophylaxis for all adults with WHO stage 3 and 4 HIV disease 
and/or with a CD4 count ≤350 cells/mm3, and regardless of CD4 count in settings where 
malaria and/or severe bacterial infections are highly prevalent [33]. For this reason, CTX 
prophylaxis is an essential component of HIV care in many settings in SSA, and its uptake 
may be used as an indicator of access to HIV care [19, 51]. However, only a small number of 
studies included in this review had data on the uptake of CTX. In Kenya and Uganda where 
routine CTX prophylaxis is recommended irrespective of CD4 count or clinical stage [49, 
50], uptake was high (>70%) irrespective of whether or not additional interventions were 
applied. This may be because CTX is widely available, inexpensive, and simple to use [52]. 
In contrast and in spite of facilitated linkage, uptake of CTX prophylaxis among those 
eligible (based on guidelines that were in use at the time of the studies) in South Africa was 
low (≤33%). The reasons for this are not clear. However previous studies have found 
irregular supply and lack of stocks of CTX, lack of awareness among health care workers, 
and perceived low priority of CTX prophylaxis due to the absence of a reporting requirement, 
to be some of the barriers to implementation of CTX prophylaxis policies [53].  
 
Consistent with previous findings [11], significant proportions of HIV-positive persons 
identified through HBHCT were still ineligible for ART (based on national guidelines that 
were in use at the time of the respective studies). The finding that ART uptake was highest in 
the studies where services were provided through community-based research clinics may be 
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attributed to such clinics being more accessible and less prone to limitations that characterise 
many public sector ART care programmes in SSA, including the requirement for several 
visits to prepare patients for ART [14], crowded, busy and unwelcoming clinics [54], non-
functioning laboratories [54], and inadequate supply or lack of antiretroviral drugs [55]. 
Additionally, some research clinics are likely to have close and long standing relationships 
with communities in which they are located.  
 
HBHCT studies with facilitated linkage have been shown to achieve higher ART initiation 
rates among participants who link to care compared to those without facilitated linkage [9]. 
However, ART initiation rates were high in some but not all studies with facilitated linkage 
described in this review. Additionally, some studies without facilitated linkage achieved 
higher ART initiation rates [47] than those with facilitated linkage [13, 14, 18, 22, 24, 44, 
45]. It is likely that clinic level factors such as those mentioned above as well as individual-
level confounding factors such as HIV disease stage may be more important in influencing 
events after linkage to care. Also, people who link to care in the absence of facilitated linkage 
may be more motivated to receive care.  
 
This review has some limitations. The review was limited to SSA. Even so, the number of 
relevant studies found is small and represents only six countries, four of which are in 
Southern Africa. This may limit the generalizability of the findings. The methodologies used 
in the identified studies varied widely, making it impractical to combine findings from 
individual studies into a pooled analysis. Outcome assessments in most of the included 
studies were based solely on self-reports or records in HIV clinics within the respective study 
areas; hence linkage to care may have been overestimated in the case of self-reports or 
underestimated if some individuals linked to clinics outside of their communities.  
 
Importantly, most of the studies that included interventions to facilitate linkage to HIV care 
were observational, determining intervention effects without control groups. A major 
limitation of observational studies is that it is difficult to account for the effects of 
confounding factors such as HIV disease stage, fear of stigma, healthcare seeking behaviour, 
and familiarity with the health care services. Moreover, in some of the studies, two or more 
interventions were delivered concurrently, making it difficult to distinguish the effects of 
each. Randomised trials represent the gold-standard methodology in the evaluation of an 
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intervention including its likely effect size [56]. It is therefore desirable to confirm the impact 
and establish the cost effectiveness of these interventions in randomised controlled trials. 
Indeed, a number of trials have been designed to investigate the effect of different 
interventions on linkage to care among persons that test HIV positive through HBHCT [57-
61]. Findings from these trials are expected in the near future and may provide more robust 
data on the impact of interventions on linkage to care after HBHCT. 
 
Except for one study in which some of the newly identified HIV-positive individuals were 
offered immediate ART irrespective of CD4 count [24], all the other studies were conducted 
in the context of old ART eligibility criteria i.e. CD4 counts of ≤200 cells/μL, ≤250 cells/μL, 
≤350 cells/μL or ≤500 cells/μL and by implication, prolonged pre-ART care periods. 
Therefore, the extent to which the findings of this review are relevant to settings in which the 
new WHO recommendation of immediate ART initiation irrespective of CD4 count [33] has 
been adopted is not clear. A future review of the evidence on linkage to care after HBHCT 
under the new treatment guidelines will be needed.  
 
In conclusion, we found that only few published studies investigated linkage to HIV care 
among adults newly diagnosed with HIV through HBHCT in SSA. In general, HBHCT 
without additional intervention strategies to increase service uptake achieved inadequate 
linkage while HBHCT combined with some kind of additional strategy seemed to achieve 
higher linkage. There is a need to confirm the impact of the most promising linkage strategies 
through randomised controlled trials before they can be recommended for large scale 
adoption. Moreover, it will be important to demonstrate the effectiveness of linkage strategies 
under the new WHO treat-all policy.  
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Figure 1: Systematic search flow diagram 
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Table 1: Description of studies included in the systematic review 
Author, year  Country, 
setting 
Study 
period 
Study design Age 
eligibility 
(years) 
HIV 
care 
provider 
CD4 ART 
eligibility 
threshold 
(cells/μL) 
Linkage to 
care 
definition 
Linkage 
assessment 
time 
(months) 
Linkage 
strategies 
Number in 
analysis 
(Number of 
HIV-positive 
persons in 
study)a 
Linked  Initiated 
CTXb  
Eligible for 
ARTc  
Initiated 
ART  
n (%, 95% 
CI) 
n/N (%, 
95% CI) 
n (%, 95% 
CI) 
n (%, 95% 
CI) 
Genberg, 
2015 [12] 
Kenya, 
rural 
2009-
2011 
Retrospective 
population-
based cohort 
study of 
HBHCT among 
participants 
enrolled in a 
clinical care 
program 
≥13 Public 
clinic  
≤250 Registration 
at clinic  
3 Referral only 1329 (3482) 109 (8.2, 
6.8-9.8) 
Not 
reported 
41 (37.6, 
28.5-47.4)  
23 (56.1, 
39.7-71.5) 
Dalal, 2013 
[19] 
Kenya, 
rural & 
urban  
2008 Prospective 
population-
based cohort 
study of 
HBHCT among 
participants 
enrolled in a 
disease 
surveillance 
program 
All agesd Public 
clinic 
≤250 Registration 
at clinic  
1 Referral only 1637 (2759) 414 (25.3, 
23.2-27.5) 
375/414 
(90.6, 87.3-
93.2) 
120 (29.0, 
24.7-33.6) 
39 (33.0, 
24.2-41.7) 
Wringe, 2012 
[47] 
Malawi, 
rural  
2008-
2010 
Retrospective 
population-
based cohort 
study of 
HBHCT among 
participants 
enrolled in a 
demographic 
surveillance 
program 
≥15 Research 
clinic  
≤250 Screening for 
ART 
eligibility 
12  Referral only 431 (473) 126 (29.2, 
24.9-33.8) 
Not 
reported 
67 (53.2, 
44.1-62.1) 
63 (94.0, 
85.4-98.3) 
Parker, 2015 
[21] 
Swaziland
, rural  
2013 Prospective 
population-
based 
intervention of 
HBHCT versus 
mobile HCT 
≥18 
months 
Public 
clinic 
≤350 Registration 
at clinic  
6  Referral only 142 (170) 45 (31.7, 
24.1-40.0) 
Not 
reported 
17 (37.8, 
23.8-53.5) 
9 (52.9, 
27.8-77.0) 
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Author, year  Country, 
setting 
Study 
period 
Study design Age 
eligibility 
(years) 
HIV 
care 
provider 
CD4 ART 
eligibility 
threshold 
(cells/μL) 
Linkage to 
care 
definition 
Linkage 
assessment 
time 
(months) 
Linkage 
strategies 
Number in 
analysis 
(Number of 
HIV-positive 
persons in 
study)a 
Linked  Initiated 
CTXb  
Eligible for 
ARTc  
Initiated 
ART  
n (%, 95% 
CI) 
n/N (%, 
95% CI) 
n (%, 95% 
CI) 
n (%, 95% 
CI) 
Velen, 2016 
[23] 
South 
Africa, 
rural & 
urban 
2013-
2014 
Prospective 
cohort study of 
HBHCT among 
household 
contacts of TB 
index patients 
enrolled in a 
TB contact 
tracing trial 
≥14 Public 
clinic 
≤350 Registration 
at clinic  
3 Referral only 25 (26)  8 (32.0, 
14.9-53.5) 
Not 
reported 
Not 
reported 
Not 
reported 
Iwuji, 2016 
[24] 
South 
Africa, 
rural  
2012-
2014 
Community-
based cluster 
randomised 
trial of 
immediate 
ART 
initiation 
versus ART 
initiation 
according to 
national 
guidelines 
following 
HBHCT 
≥16 Public & 
research 
clinics 
Any CD4 
count 
(intervention 
arm); ≤350 
(standard-of-
care arm) 
Registration 
at clinic  
12 Referral & 
follow-up 
counsellinge 
358 (2569) 162 (45.3, 
40.0-50.6) 
Not 
reported 
101 (71.6, 
63.4-78.9)f 
81 (80.2, 
71.1-87.5) 
Naik, 2015 
[45] 
South 
Africa, 
rural 
2009-
2011 
Prospective 
population-
based cohort of 
participants 
offered 
HBHCT as a 
standard-of-
care service & 
in the context 
of a trial of 
HBHCT versus 
facility-based 
HCT. 
≥14 Public 
clinic 
≤200  Obtaining a 
CD4 count 
 
3 Referral & at 
least 3 
follow-up 
counselling 
visitsg 
410 (492) 248 (60.5, 
55.6-65.3) 
Not 
reported 
41 (16.5, 
12.1-21.8) 
33 (80.5, 
65.1-91.2) 
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Author, year  Country, 
setting 
Study 
period 
Study design Age 
eligibility 
(years) 
HIV 
care 
provider 
CD4 ART 
eligibility 
threshold 
(cells/μL) 
Linkage to 
care 
definition 
Linkage 
assessment 
time 
(months) 
Linkage 
strategies 
Number in 
analysis 
(Number of 
HIV-positive 
persons in 
study)a 
Linked  Initiated 
CTXb  
Eligible for 
ARTc  
Initiated 
ART  
n (%, 95% 
CI) 
n/N (%, 
95% CI) 
n (%, 95% 
CI) 
n (%, 95% 
CI) 
Labhardt, 
2014 [22] 
Lesotho, 
rural  
2011 Community-
based cluster 
randomised 
trial of HBHCT 
versus mobile 
HCT  
All ages  Public 
clinic 
≤350 Registration 
at clinic  
1 Referral & 
POC CD4 
count testing 
37 (39) 9 (24.3, 
11.8-41.2) 
Not 
reported  
7 (77.8, 
40.0-97.2) 
1 (14.3, 
0.36-57.9) 
Becker, 2014 
[46] 
Malawi, 
peri-urban 
2009 Population-
based 
uncontrolled 
intervention 
study of couple 
HBHCT & 
couple family 
planning 
services 
15-49 
(female); 
≥15 
(male) 
Public 
clinic 
≤250 Registration 
at clinic  
1 week Referral & 
provision of 
funds for 
transport to 
clinic to 
participants 
who disclosed 
their HIV 
status to their 
partnersh 
15 (46)  8 (53.3, 
26.6-78.7) 
Not 
reported 
Not 
reported 
Not 
reported 
Nakigozi, 
2011 [43] 
Uganda, 
rural  
2005-
2008 
Retrospective 
population-
based cohort of 
participants 
receiving 
HBHCT or 
other 
community-
based HCT in 
an HIV 
surveillance 
program 
15-49 Research 
clinic 
≤250 Registration 
at clinic  
6 Referral & 
follow-up 
counsellingi 
1137 (1451) 781 (68.7, 
65.9-71.4) 
781/781 
(100.0) 
237 (30.3, 
27.1-33.7) 
225 (94.9, 
91.3-97.4) 
Tumwebaze, 
2012 [44] 
Uganda, 
rural & 
peri-urban 
2010-
2011 
Population-
based 
uncontrolled 
intervention 
study of 
HBHCT & a 
combination of 
linkage 
strategies 
≥18 Public 
clinic 
≤250 Registration 
at clinic  
3 Referral, CD4 
count 
laboratory 
testing 
(results 
returned to 
participant a 
week later), 
& follow-up 
counselling 
(1, 2 & 3 
months) 
77 (152) 63 (81.8, 
71.4-89.7) 
63/63 
(100.0) 
13 (20.6, 
11.5-32.7) 
8 (61.5, 
31.6-86.1) 
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Author, year  Country, 
setting 
Study 
period 
Study design Age 
eligibility 
(years) 
HIV 
care 
provider 
CD4 ART 
eligibility 
threshold 
(cells/μL) 
Linkage to 
care 
definition 
Linkage 
assessment 
time 
(months) 
Linkage 
strategies 
Number in 
analysis 
(Number of 
HIV-positive 
persons in 
study)a 
Linked  Initiated 
CTXb  
Eligible for 
ARTc  
Initiated 
ART  
n (%, 95% 
CI) 
n/N (%, 
95% CI) 
n (%, 95% 
CI) 
n (%, 95% 
CI) 
Barnabas, 
2014 [13] 
South 
Africa & 
Uganda, 
rural 
2011-
2013 
Population-
based 
uncontrolled 
intervention 
study of 
HBHCT & a 
combination of 
linkage 
strategies 
≥18 Public 
clinic 
≤350  Registration 
at clinic  
12 Referral, POC 
CD4 count 
testing, 
follow-up 
counselling 
(1, 3, 6, 9, & 
12 months), 
& viral load 
testing (0 & 6 
months) 
229 (635) 227 (99.1, 
96.9-99.9)  
2/12 (16.7, 
2.1-48.4) 
SA; 86/110 
(78.2, 69.3-
85.5) UG 
74 (32.6, 
26.5-39.1) 
59 (79.7, 
68.8-88.2) 
van Rooyen, 
2013 [18] 
South 
Africa, 
rural 
2011-
2012 
Population-
based 
uncontrolled 
intervention 
study of 
HBHCT & a 
combination of 
linkage 
strategies 
≥18 Public 
clinic 
≤200; ≤350 
(from August 
2011) 
Registration 
at clinic  
6  Referral, POC 
CD4 count 
testing, & 
follow-up 
counselling 
(1, 3, & 6 
months) 
73 (201) 70 (95.9, 
88.5-99.1) 
Not 
reported 
35 (50.0, 
37.8-62.2) 
19 (54.3, 
36.6-71.2) 
Barnabas, 
2016 [14] 
South 
Africa & 
Uganda, 
rural 
2013-
2015 
Household 
randomised 
controlled trial 
of referral only 
versus referral 
plus other 
linkage 
strategies after 
HIV diagnosis 
through 
HBHCT or 
mobile HCT (6 
linkage 
strategies)j 
≥16 Public 
clinic 
≤350; ≤500 
(from January 
2015)  
Registration 
at clinic  
9 Referral only  82 (226) 70 (85.4, 
75.8-92.2) 
2/6 (33.0, 
4.3-77.7) 
SA; 20/25 
(80.0, 59.3-
93.2) UG 
37 (52.9, 
40.6-64.9) 
28 (75.7, 
58.8-88.2) 
Referral & 
POC CD4 
count testing  
81 (213) 73 (90.1, 
81.5-95.6) 
1/4 (25.0, 
0.63-80.6) 
SA; 37/38 
(97.4, 86.2-
99.9) UG 
43 (58.9, 
46.8-70.3) 
25 (58.1, 
42.1-73.0) 
Referral & 
counsellor 
clinic linkage 
facilitation 
104 (231) 102 (98.1, 
93.2-99.8) 
1/3 (33.3, 
0.84-90.6) 
SA; 18/21 
(85.7, 63.7-
97.0) UG 
51 (50.0, 
39.9-60.1) 
39 (76.5, 
62.5-87.2) 
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Author, year  Country, 
setting 
Study 
period 
Study design Age 
eligibility 
(years) 
HIV 
care 
provider 
CD4 ART 
eligibility 
threshold 
(cells/μL) 
Linkage to 
care 
definition 
Linkage 
assessment 
time 
(months) 
Linkage 
strategies 
Number in 
analysis 
(Number of 
HIV-positive 
persons in 
study)a 
Linked  Initiated 
CTXb  
Eligible for 
ARTc  
Initiated 
ART  
n (%, 95% 
CI) 
n/N (%, 
95% CI) 
n (%, 95% 
CI) 
n (%, 95% 
CI) 
Referral, POC 
CD4 count 
testing, & 
counsellor 
clinic linkage 
facilitation 
72 (206) 69 (95.8, 
88.3-99.1) 
0/3 (0.0) 
SA; 23/27 
(85.2, 66.3-
95.8) UG 
43 (62.3, 
49.8-73.7) 
23 (53.5, 
37.7-68.8) 
Referral & 
follow-up 
counselling 
(1, 3, & 6 
months)  
87 (229) 80 (92.0, 
84.1-96.7) 
0/12 (0.0) 
SA; 30/30 
(100.0) UG 
41 (51.3, 
39.8-62.6) 
31 (75.6, 
59.7-87.6) 
Referral, POC 
CD4 count 
testing & 
follow-up 
counselling 
(1, 3, & 6 
months) 
85 (220) 81 (95.3, 
88.4-98.7) 
1/5 (20.0, 
0.51-71.6) 
SA; 28/28 
(100.0) UG 
46 (56.8, 
45.3-67.8) 
36 (78.3, 
63.6-89.1) 
aOnly adults (≥18 years) newly diagnosed with HIV through HBHCT were included in the analysis. 
bUptake of CTX prophylaxis is shown separately for South Africa (SA) and Uganda (UG) because eligibility criteria are different in each country.  
cBased on locally recommended CD4 count eligibility threshold during the study period. 
dChildren aged <13 years were offered HBHCT if their biological mothers were HIV-positive or deceased 
eFollow-up counselling was offered to individuals who did not link to care within 3 months of referral; number and timing of follow-up visits were not specified. 
fInformation on ART eligibility and initiation was not available for persons who linked to the public health facilities. Hence, the denominator used for ART eligibility (n=141) is the number of persons who linked to the research 
clinics.  
gTiming of follow-up visits was not specified. 
hThe number of participants who disclosed their HIV status to their partners was not reported. 
iNumber and timing of follow-up visits were not specified. 
jResults for linkage to care and other outcomes are presented separately for each of the six linkage strategies.  
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Table 2: Risk of bias within studies  
Author, year Selection of participantsa  Outcome ascertainmentb  Loss to follow-upc 
Genberg, 2015 [12] HBHCT coverage could not be estimated because the size of the 
target population was not reported. Unclear risk 
Clinic-verified data. No information on persons who may have 
linked to clinics outside the study area. Unclear risk 
 No participant 
follow-up 
Dalal, 2013 [19] HBHCT coverage was 82%. Low risk  Self-report for all participants. High risk 48% (881/1839) loss 
to follow-up. High 
riskd 
Wringe, 2012 [47] HBHCT coverage could not be estimated because the total 
number of persons in the target population was not reported. 
Unclear risk 
Clinic-verified data. No information on persons who may have 
linked to clinics outside the study area. Unclear risk 
No participant follow-
up 
Parker, 2015 [21] HBHCT was conducted in only 26% of households in the target 
area due to time constraints. It is not clear how these households 
were selected. High risk  
Clinic-verified data. Participants who were referred health 
facilities outside the study area were excluded from analysis. 
Unclear risk 
No participant follow-
up 
Velen, 2016 [23] HBHCT was offered to household contacts of TB patients 
selected through convenience sampling. High risk 
Self-report for all participants. High risk 12% (3/26) loss to 
follow-up. Low risk 
Iwuji, 2016 [24] HBHCT coverage was 64%. High risk Clinic verified data. No information on persons who may have 
linked to clinics outside the study area. Unclear risk 
16% (58/358) loss to 
follow-up. Low riske 
Naik,2015 [45] HBHCT coverage could not be estimated because the size of the 
population targeted for testing in the participating communities 
was not reported. Unclear risk  
Self-report & clinic-verified data or self-report only (29% of 
participants). High risk 
18% (79/438) loss to 
follow-up. Low riskf 
Labhardt, 2014 [22] HBHCT coverage could not be estimated because the total 
number of persons in the target population was not reported. 
Unclear risk 
Clinic-verified data. No information on persons who may have 
linked to clinics outside the study area. Unclear risk 
No participant follow-
up 
Becker, 2014 [46] HBHCT was offered to all eligible participants in one village 
and approximately one-third in two other villages (no 
information on how participants in these two villages were 
selected). High risk  
Self-report for all participants. High risk 2% (1/46) loss to 
follow-up. Low risk 
Nakigozi, 2011 [43] Annual HIV testing coverage in the cohort is >90%. However, 
21% of the persons who tested HIV-positive were excluded 
from the analysis because they had either refused to learn their 
HIV results (3%) or received their HIV result less than six 
months before data-set closure (18%). High risk  
Self-report & clinic-verified data. No information on whether 
self-reported linkage was confirmed with clinic records for all 
participants. Unclear risk 
Loss to follow-up not 
reported. Unclear risk 
Tumwebaze, 2012 [44] HBHCT coverage was 80%. Low risk Self-report for all participants. High risk 2% (3/152) loss to 
follow-up. Low risk 
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Author, year Selection of participantsa  Outcome ascertainmentb  Loss to follow-upc 
Barnabas, 2014 [13] HBHCT coverage was 96%. Low risk Self-report & review of documentation issued to patient by the 
HIV clinic. Low risk 
10% (62/635) loss to 
follow-up. Low risk 
van Rooyen, 2013 [18] HBHCT coverage was 91%. Low risk Self-report & review of documentation issued to patient by the 
HIV clinic. Low risk 
2% (5/201) loss to 
follow-up. Low risk 
Barnabas, 2016 [14] HBHCT coverage could not be estimated because the size of the 
population targeted for testing in the participating communities 
was not reported. Unclear risk  
Self-report & review of documentation issued to patient by the 
HIV clinic. Low risk 
3% (40/1325) loss to 
follow-up. Low risk 
aIn population-based studies, there was low risk of bias if HBHCT coverage (defined as the number of persons accessing HBHCT out of the total resident population) was ≥80%, high 
risk if HBHCT coverage was <80% and unclear risk if there was no information on coverage. In non-population based cohort studies, there was low risk if participants were randomly 
selected, high risk if the selection was non-random and unclear risk if there was insufficient information on participant selection.  
bThere was low risk of bias if ascertainment of linkage to care was by both self-report & examination of HIV clinic records or documentation issued to patients by the HIV clinic for 
≥80% of the participants, high risk if ascertainment was by self-report only and unclear risk if there was insufficient information on ascertainment of linkage outcomes for some study 
participants.  
cThere was low risk if retention of HIV-positive persons identified through HBHCT was ≥80%, high risk if retention was <80% and unclear risk if information was not available. 
dOnly applicable to HIV-positive individuals who were newly identified through HBHCT.  
eOnly applicable to newly identified HIV-positive persons who were referred to care at least 12 months before the end of the first phase of the trial i.e. May 2014. 
fOnly applicable to HIV-positive individuals who were not engaged in care at baseline.  
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